Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements regarding the timing of potential commercial launch of NGX- 4010; the timing of filings for regulatory approval and the indications potentially being sought in such filings; the indications for which NGX-4010 may be approved for use; the potential markets for NGX-4010; the potential efficacy and benefits of NGX-4010; the potential use of data from the recently completed clinical trial in HIV-DSP to support efficacy; and NeurogesX' plans to commercialize NGX-4010, including with respect to sales force plans and plans to enter into commercial partnerships. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, data from the recently completed clinical trial in HIV-DSP may have an effect on the potential regulatory approval of NGX-4010, and approved indications of such approval, if any; positive results in certain clinical trials may not be sufficient to obtain FDA or European regulatory approval; subsequent analysis of data from NeurogesX' past clinical trials may cause the results to be viewed less favorably as compared to the initial analysis of such results; past results of clinical trials may not be indicative of future clinical trials results; NGX-4010 may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use NGX- 4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies and changing standards of care; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; NeurogesX' ability to obtain additional financing; NeurogesX' ability to obtain and maintain futur
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ) today ... quarter of 2013 on Monday, February 3, 2014. A press ... close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... the operating highlights and financial results for the fourth quarter ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... May 26 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) ... make a presentation regarding the business strategy of the Company at the Noble ... 1:00 p.m. EDT .  The conference will be held at the Hard Rock ... , , ...
... Inteplast Group,s Integrated Bagging Systems (IBS) Unit is ... packaging division from Uniflex Holdings, part of S. Walter Packaging ... and other medical packaging, and is a valued addition to ... name, sales and customer base into the Inteplast fold. , ...
Cached Medicine Technology:Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010 2Inteplast Acquires Medical Packaging Division 2
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... media and others interested in the chemical sciences are ... American Chemical Society (ACS) Webinars, focusing on how to ... programs. Scheduled for Thursday, Sept. 16, from 2 ... feature Josephine Yuen, Ph.D., NSF Program Director, speaking on ...
... for Personalized Medicine , Author: Shara Yurkiewicz, Summary: Ten ... the human genome, major changes have made their way ... Title: Personalized Medicine,s Ragged Edge, Author: Leonard M. Fleck, ... spin. But little attention has been given to some ...
... , THURSDAY, Sept. 9 (HealthDay News) -- A ... heads-up about the kinds of medical problems that may face ... to use a computational method to create a score based ... rate during the first three hours after birth. In a ...
... living in California, Laotian/Hmong-Americans have the lowest survival rates ... new study by researchers with the UC Davis School ... largest population-based examination of liver cancer rates among Asian-Americans, ... to detect and treat the disease earlier among Laotian/Hmong-Americans, ...
... Academy of Orthopaedic Surgeons (AAOS) recently approved and released ... periprosthetic joint infections of the hip and knee. Clinical ... ensure that patients receive high quality care. A ... organisms enter the wound during or at any point ...
... By Steven Reinberg HealthDay Reporter , ... their ability to lower cholesterol and prevent heart attacks ... rheumatoid arthritis, Israeli researchers report. "We ... were less likely to develop rheumatoid arthritis over a ...
Cached Medicine News:Health News:American Chemical Society Webinar focuses on NSF's small business funding programs 2Health News:The Hastings Center Report table of contents for September-October 2010 2Health News:The Hastings Center Report table of contents for September-October 2010 3Health News:New Tool Aims to Predict Problems in Preemies 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 2Health News:UC Davis study finds low liver cancer survival rates among Laotian/Hmong-Americans 3Health News:Joint replacement: Does this look infected to you? 2Health News:Joint replacement: Does this look infected to you? 3Health News:Statins May Guard Against Rheumatoid Arthritis 2Health News:Statins May Guard Against Rheumatoid Arthritis 3
... Handbook on Injectable Drugs is a ... it quick and easy to check ... you enter the selected drugs, clear ... so you can quickly take clinical ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
... DrDrugs®: Drug Guide for ... over 760 Integrated Calculators ... comprehensive, up-to-date and practical ... in drug dosing calculation ...
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician....
Medicine Products: